Reirradiation for Locoregional Recurrent Breast Cancer

医学 不良事件通用术语标准 四分位间距 不利影响 乳腺癌 放射治疗 核医学 癌症 内科学
作者
Sayeh Fattahi,Safia K. Ahmed,Sean S. Park,Ivy A. Petersen,Dean A. Shumway,Bradley J. Stish,Elizabeth Yan,Nicholas B. Remmes,Robert W. Mutter,Kimberly S. Corbin
出处
期刊:Advances in radiation oncology [Elsevier]
卷期号:6 (1): 100640-100640 被引量:37
标识
DOI:10.1016/j.adro.2020.100640
摘要

Reirradiation poses a distinct therapeutic challenge owing to risks associated with exceeding normal tissue tolerances and possibly more therapeutically resistant disease biology. We report our experience with reirradiation for locoregional recurrent or second primary breast cancer.Between 1999 and 2019, all patients with breast cancer treated with repeat breast/chest wall radiation therapy (RT) at our institution were identified. Adverse events were assessed using the Common Terminology Criteria for Adverse Events v5.0. Fisher exact, Mann-Whitney rank-sum, and unpaired t tests were used for statistical analysis. Freedom from locoregional recurrence and distant metastasis as well as overall survival were calculated using the Kaplan-Meier method.Seventy-two patients underwent reirradiation. Median prior RT dose, reirradiation dose, and cumulative dose were 60 Gy (interquartile range [IQR], 50-60.4 Gy), 45 Gy (IQR, 40-50 Gy), and 103.54 Gy2 (IQR, 95.04-109.62 Gy2), respectively. Median time between RT courses was 73 months (IQR, 29-129 months). Thirty-four patients (47%) had gross residual disease at time of reirradiation. Course intent was described as curative in 44 patients (61%) and palliative in 28 (39%). Fifty-two patients (72%) were treated with photons ± electrons and 20 (28%) with protons. With a median follow-up of 22 months (IQR, 10-43 months), grade 3 adverse events were experienced by 13% of patients (10% acute skin toxicity and 3% late skin necrosis). Time between RT courses and reirradiation fields was significantly associated with the development of grade 3 toxicity at any point. Proton therapy conferred a dosimetric advantage without difference in toxicity. At 2 years, locoregional recurrence-free survival was 74.6% and overall survival was 65.5% among all patients, and 93.1% and 76.8%, respectively, among curative intent patients treated without gross disease. Distant metastasis-free survival was 59.0% among all curative intent patients.Reirradiation for locoregional recurrent breast cancer is feasible with acceptable rates of toxicity. Disease control and survival are promising among curative intent reirradiation patients without gross disease.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
慕青应助Jae采纳,获得10
4秒前
sjx_13351766056完成签到 ,获得积分10
5秒前
李大刚完成签到 ,获得积分10
5秒前
研友_85yrY8发布了新的文献求助10
6秒前
yjy完成签到 ,获得积分10
11秒前
碧蓝巧荷完成签到 ,获得积分10
11秒前
断章完成签到 ,获得积分10
12秒前
科研怪人完成签到 ,获得积分10
13秒前
15秒前
武大帝77完成签到 ,获得积分10
18秒前
二毛完成签到,获得积分10
24秒前
感动依霜完成签到 ,获得积分10
29秒前
闪闪的谷梦完成签到 ,获得积分10
33秒前
36秒前
44秒前
zw完成签到,获得积分0
48秒前
权小夏完成签到 ,获得积分10
53秒前
kehe!完成签到 ,获得积分0
56秒前
NeoWu完成签到,获得积分10
58秒前
LJ_2完成签到 ,获得积分10
1分钟前
兔兔完成签到 ,获得积分10
1分钟前
故意的冰淇淋完成签到 ,获得积分10
1分钟前
courage完成签到,获得积分10
1分钟前
伶俐的语雪完成签到,获得积分10
1分钟前
小幸运R完成签到 ,获得积分10
1分钟前
科研小郭完成签到,获得积分10
1分钟前
轩辕剑身完成签到,获得积分0
1分钟前
常温完成签到,获得积分10
1分钟前
CipherSage应助yuri采纳,获得10
1分钟前
吃葡萄不吐完成签到,获得积分10
1分钟前
水星完成签到 ,获得积分10
1分钟前
英俊的铭应助吃葡萄不吐采纳,获得10
1分钟前
mianmian0118完成签到 ,获得积分10
1分钟前
陈荣完成签到 ,获得积分10
1分钟前
2分钟前
yellow发布了新的文献求助10
2分钟前
巾凡完成签到 ,获得积分10
2分钟前
张润泽完成签到 ,获得积分10
2分钟前
yuri完成签到,获得积分10
2分钟前
高分求助中
Histotechnology: A Self-Instructional Text 5th Edition 2000
Effect of reactor temperature on FCC yield 1700
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
Uncertainty Quantification: Theory, Implementation, and Applications, Second Edition 800
Production Logging: Theoretical and Interpretive Elements 555
电解铜箔实用技术手册 540
Organic Synthesis 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3284383
求助须知:如何正确求助?哪些是违规求助? 2921686
关于积分的说明 8406990
捐赠科研通 2593344
什么是DOI,文献DOI怎么找? 1413855
科研通“疑难数据库(出版商)”最低求助积分说明 658674
邀请新用户注册赠送积分活动 640407